While the dollar amount is not massive relative to market cap, the fact that all three named executives sold simultaneously, especially the CEO, suggests a lack of near-term conviction. Traders should watch for potential softness in upcoming earnings or pipeline updates.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $66.61entry
- T+1 · 8mo ago +0.18%α +0.09% · $66.73
- T+5 · 7mo ago −3.03%α −6.80% · $64.59
- T+20 · 7mo ago −3.96%α −13.64% · $63.97
- T+60 · 5mo ago +31.00%α +17.91% · $87.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three corporate insiders at Cytokinetics sold shares in the past week, totaling $964K in open-market dispositions. CEO Robert Blum accounted for over half the volume, selling $500K worth of stock, while two other executives sold smaller amounts. All trades occurred at prices between $65.00 and $66.63.
Key Financial Metrics
Key Facts
- CEO Robert Blum sold $500K in stock, representing the largest single transaction in the cluster.
- Two other executives, EVPs, sold a combined $465K in shares over the same period.
- Total open-market selling by insiders amounts to $964K, or approximately 0.012% of the company's $8.1B market cap.
- All sales occurred at market prices between $65.00 and $66.63, indicating no block discount or distressed sale.
- No open-market purchases were reported; all transactions were sales or non-cash derivative exercises.
Financial Impact
$964,000 in insider selling over 7 days
Risk Factors
- Perception of insider pessimism, particularly given CEO participation.
- Potential for negative sentiment ripple in a high-beta biotech stock despite modest dollar volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1775679566910 |
Track record
46 reports on CYTK
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers